



# NATURAL + NOVEL PSYCHEDELICS

INTEGRATED DRUG DEVELOPMENT & MANUFACTURING



# STRATEGY



## PSYCHEDELIC MANUFACTURING

Natural & Synthetic



## INTELLECTUAL PROPERTY

Novel Molecules



## CLINICAL TRIALS & UNIVERSITY RESEARCH

# TRACTION

## 01 DRUG DEVELOPMENT

Unique Pipeline: Hybrid Non-hallucinogenic Molecules

## 02 PSYCHEDELICS

Controlled Substance **Dealers License** From Health Canada

## 03 INTELLECTUAL PROPERTY

CB-001 Natural Psilocybin Isolate, CB-002 Ocelot Hybrid New Chemical Entities, CB-003 Full Tryptamine Strain-specific Mushroom Pill

## 04 UNIVERSITY RESEARCH

**McGill University** – Psilocybin Reward & Self Esteem in rats  
**University of Cambridge and Duke University:** 5-MeO-DMT success with PTSD patient

## 05 OPERATIONS

Vertically Integrated: Research, Development & Manufacturing

## 06 FUNDRAISING

CAD \$6.5 Million Raised, 225 Investors Including many Doctors

## 07 PARTNERSHIP

Preclinical CRO Partnership Accelerates Molecule Development

## 08 LISTING STRATEGY

Nasdaq Ticker Reserved, US \$10M P.I.P.E. & \$15 Million ELOC Termsheets, Convertible Debenture

## 09 R&D

SRED Claim of \$530,000 made to Canadian Revenue Agency. Expecting refund in Q4 2025

## 10 REVENUE CHANNELS

- **NEAR-TERM:** Molecule Manufacturing, Clinical Supply, Out-licensing Psilocybin Isolate
- **MID-TERM:** Special Access Programs (USA, Canada, Australia)
- **LONG-TERM:** Drug Development: CB-002

# THE PROBLEM? ALTERNATIVES TO ANTIDEPRESSANTS ARE NEEDED

## 01 THE CHALLENGE OF MENTAL ILLNESS


- Depression: Major contributor to global disability
- Affects 350 million people worldwide<sup>1</sup>

## 02 LIMITATIONS OF ANTIDEPRESSANTS - SELECTIVE SEROTONIN RE-UP TAKE INHIBITORS =“SSRI’S”

- 50/50 chances of SSRI’s being effective<sup>2</sup>
- High discontinuation rate: 80% stop within a month<sup>1</sup> due to side effects & ineffectiveness
- Require chronic administration, potentially for life

## 03 TRYPTAMINES (PSILOCYBIN, LSD, ETC): A NEW APPROACH TO MENTAL HEALTH AND ADDICTION TREATMENT

- Mimics Serotonin receptor agonist
- Resets the Default Mode Network, associated with Rumination a/k/a Negative Thought Loops
- Promotes neuroplasticity and growth of



## ANTIDEPRESSANTS VS. PSYCHEDELICS COMPARISON

### ANTIDEPRESSANTS

- Increase internal serotonin by blocking re-uptake (e.g. SSRIs)
- Associated side effects: sexual dysfunction, sleep disturbance, weight changes, eating disorders, pain
- Dosing: Daily, often for life

### PSYCHEDELICS

- Introduce external serotonin-like molecules
- Offer a novel therapeutic pathway with potential for long-term benefits
- Dosing: 1 or 2 doses yield years of relief

#### SOURCES:

<https://www.theguardian.com/science/2018/feb/21/the-drugs-do-work-antidepressants-are-effective-study-shows>  
<https://www.psych.ox.ac.uk/news/the-guardian-no-new-antidepressants-likely-in-next-decade>  
<https://www.nature.com/articles/s41593-023-01316-5>

# THE SOLUTION... NATURAL ENTHEOGENS

→ MUSHROOMS

→ CACTUS

→ AYAHUASCA = DMT + HARMALAS

Psychedelics, or Natural Entheogens, are psychoactive substances derived from plants or fungi that have been traditionally used in religious or spiritual rituals to induce altered states of consciousness.

Cubed is federally licensed to produce all of the following psychedelic molecules both naturally and synthetically.

## MOLECULE CATALOGUE



**PSILOCYBIN**

Natural & Synthetic



**PSILOCIN**

Synthetic



**MDMA**

Synthetic



**MESCALINE**

Natural & Synthetic



**5-MEO-DMT**

Synthetic



**LSD**

Synthetic



**DMT**

Natural & Synthetic



**HARMALAS**

Natural & Synthetic



**OCELOT**

Novel Chemical Entities

# MANUFACTURING CAPABILITIES



## MYCOLOGY - MUSHROOM CULTIVATION

- Our world-class genetic library of psilocybe cubensis strains include modern mutant strains with up to 1.5% total tryptamines and high cultivation yields.
- Our cultivation methods include bag and box methods and we grow mycelia ("roots") in bioreactors



## EXTRACTION CAPABILITIES

- EXTRACTION METHOD: Soxhlet extraction with methanol & water
- CURRENT CAPACITY= 300 kg / year dried mushrooms input
- FUTURE PHASE 2 EXPECTED CAPACITY= 6,000 kg / year with \$150,000 capex required



## SCALABLE PHARMA-GRADE MOLECULES

- Cubed produces synthetic psychedelic molecules in addition to our natural psychedelic portfolio
- Faster production & easier to scale than natural entheogens, up to 1KG API molecule per week.
- Allows us to produce API's and Finished Drug Products for clinical trials & commercialization

# TEAM

## ADAM B. COAPE-ARNOLD CEO, S/PIC, DIRECTOR, FOUNDER

- Marketed & branded 7 companies w/ annual sales over \$10 million.
- Vice Chairman & Board Director, PsyCan, a not-for-profit trade association representing Canadian psychedelic companies.

## ANTHONY ROSSI PRESIDENT, DIRECTOR, CO-FOUNDER

- Instrumental in key financing rounds and scaling 4 psychedelic RTO's.
- Former Director and VP of multiple public companies.
- Top 30 under 30 Award, 2016 E&Y Entrepreneur of the Year Nominee.

## DOUGLAS COAPE-ARNOLD FINANCIAL ADVISOR / DIRECTOR

- Over \$1 billion raised in capital market transactions & private equity fundraising over 30 years.
- Corporate board governance experience with 5 directorships.

## DAVID FARRIS EVP, BIZDEV / CO-FOUNDER

- Experience with growing start-ups and building brands.
- Executed on multiple fundraising initiatives.

## GLENN COPELAND, MD CHIEF MEDICAL OFFICER (EMERITUS)

- Cleveland Clinic Canada, Founder, Former Chairman & CEO.
- Mount Sinai Hospital, Toronto – Rehab and Wellbeing Centre, Founder & CEO.
- Toronto Blue Jays & Atlanta Braves – Team Physician

## ALEXANDRIA JEANNERET, M.A . HEAD OF CHEMISTRY

- Six years CRO experience in designing and executing syntheses of natural products & synthesizing further derivatives.
- Honours B. Sci, Biopharmaceutical Sciences, Specialization in Medicinal Chemistry, U of Ottawa
- Master's in Chemistry, University of Toronto
- Conduct effective syntheses, purification (recrystallization/chromatography) and characterization (NMR/HPLC-MS) of key target molecules

## ELOISE GRONDIN-BOUCHARD MYCOLOGY, R&D MANAGER , Q/PIC

- Experienced in regulated consumer packaged goods: Dairy (Milk, Yogurt, Ice Cream) & Cannabis
- Product developer across many domains
- Created Canadian Prime Minister's favorite yogurt

## PAVOL TUNA, MSC MEDICINAL CHEMIST, A/QPIC

- MSc. in Medicinal Chemistry, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences
- Researched Ibogaine analogs and 5-MEO- at the University of Copenhagen, Denmark

## JONATHAN SOOSAIPILLAI CPA, CGA INTERIM CFO

- Worked with 500+ small business owners across 15+ industries specializing in tax planning, cross-border financial strategies (US + Canada), M&A and JV's. • Former Director of Client Relations & Finance of a multinational company.

## DYLAN PIGEON MYCOLOGIST

- B.A.. Microbiology & Immunology, University of Montreal
- Lab & Production Manager, Mycoboutique, Montreal, QC
- Kombucha Fermentation Production Expert



# SPONSORED RESEARCH



**MCGILL**

**DISCOVERED SELF-ESTEEM & REWARD MECHANISM IN RATS USING**



**DUKE & CAMBRIDGE**

**HEALED A WOMAN WITH PTSD USING 5-MEO-DMT**

# RESEARCH

# Duke

UNIVERSITY

## ANYA RAGNHILDSTVEIT, PHD

Principal Investigator University of Cambridge

## PAUL SELI, PHD

Duke University

ANYA RAGNHILDSTVEIT, PAUL SELI, NATHANIEL BARR ET AL.

frontiers | Frontiers in Psychiatry

TYPE Case Report  
PUBLISHED 23 November 2023  
DOI 10.3389/fpsy.2023.1271152

Check for updates

### OPEN ACCESS

EDITED BY  
Jacqueline von Salm,  
Pisiera, United States

REVIEWED BY  
Tomislav Majic,  
Charité University Medicine Berlin, Germany  
Bianca Sebben,  
Conscious Insights Pty Ltd., Australia

\*CORRESPONDENCE  
Anya Ragnhildstveit  
✉ amr210@cam.ac.uk

RECEIVED 01 August 2023  
ACCEPTED 03 November 2023  
PUBLISHED 23 November 2023

CITATION  
Ragnhildstveit A, Khan R, Seli P, Bass LC,  
August RJ, Kaiyo M, Barr N, Jackson LK,  
Gaffrey MS, Barsuglia JP and Averill LA (2023)  
5-MeO-DMT for post-traumatic stress disorder:  
a real-world longitudinal case study.  
*Front. Psychiatry* 14:1271152.  
doi: 10.3389/fpsy.2023.1271152

COPYRIGHT  
© 2023 Ragnhildstveit, Khan, Seli, Bass, August,  
Kaiyo, Barr, Jackson, Gaffrey, Barsuglia and  
Averill. This is an open-access article  
distributed under the terms of the Creative  
Commons Attribution License (CC BY). The  
use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in this  
journal is cited, in accordance with accepted  
academic practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

## 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study

Anya Ragnhildstveit<sup>1,2\*</sup>, Ryan Khan<sup>1</sup>, Paul Seli<sup>1,3</sup>, Lisa Claire Bass<sup>1,4</sup>,  
River Jude August<sup>1,5</sup>, Miriam Kaiyo<sup>1,5</sup>, Nathaniel Barr<sup>6</sup>,  
Laura Kate Jackson<sup>1</sup>, Michael Santo Gaffrey<sup>3,7,8</sup>,  
Joseph Peter Barsuglia<sup>9</sup> and Lynnette Astrid Averill<sup>10,11,12</sup>

<sup>1</sup>Integrated Research Literacy Group, Draper, UT, United States, <sup>2</sup>Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom, <sup>3</sup>Department of Psychology and Neuroscience, Duke University, Durham, NC, United States, <sup>4</sup>Neuroscience Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, United States, <sup>5</sup>Department of Family and Consumer Studies, University of Utah, Salt Lake City, UT, United States, <sup>6</sup>School of Humanities and Creativity, Sheridan College, Oakville, ON, Canada, <sup>7</sup>Department of Pediatrics, Division of Pediatric Psychology and Developmental Medicine, Medical College of Wisconsin, Milwaukee, WI, United States, <sup>8</sup>Children's Wisconsin, Milwaukee, WI, United States, <sup>9</sup>The Mission Within, Baja California, Mexico, <sup>10</sup>Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, United States, <sup>11</sup>Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States, <sup>12</sup>Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States

Psychedelic therapy is, arguably, the next frontier in psychiatry. It offers a radical alternative to longstanding, mainstays of treatment, while exciting a paradigm shift in translational science and drug discovery. There is particular interest in 5-methoxy-*N,N*-dimethyltryptamine (5-MeO-DMT)—a serotonergic psychedelic—as a novel, fast-acting therapeutic. Yet, few studies have directly examined 5-MeO-DMT for trauma- or stress-related psychopathology, including post-traumatic stress disorder (PTSD). Herein, we present the first longitudinal case study on 5-MeO-DMT for chronic refractory PTSD, in a 23-year-old female. A single dose of vaporized bufotoxin of the Sonoran Desert Toad (*Inciilius alvarius*), containing an estimated 10–15 mg of 5-MeO-DMT, led to clinically significant improvements in PTSD, with next-day effects. This was accompanied by marked reductions in hopelessness and related suicide risk. Improvements, across all constructs, were sustained at 1-, 3-, 6-, and 12-months follow-up, as monitored by a supporting clinician. The subject further endorsed a complete mystical experience, hypothesized to underlie 5-MeO-DMT's therapeutic activity. No drug-related, serious adverse events occurred. Together, results showed that 5-MeO-DMT was generally tolerable, safe to administer, and effective for PTSD; however, this was not without risk. The subject reported acute nausea, overwhelming subjective effects, and late onset of night terrors. Further research is warranted to replicate and extend these findings, which are inherently limited, non-generalizable, and rely on methods not clinically accepted.

KEYWORDS  
5-methoxy-*N,N*-dimethyltryptamine, 5-MeO-DMT, psychedelic therapy, post-traumatic stress disorder, PTSD, trauma, case report

<https://www.frontiersin.org/articles/10.3389/fpsy.2023.1271152/full>

# RESEARCH

---



# McGill

## ROSEMARY BAGOT, PHD

Principal Investigator

---



## BAGOT LAB

### RESEARCH UPDATE: UNDERSTANDING REWARD PATHWAYS IN THE BRAIN

Working with a CQDM grant of \$575,000, Dr. Rosemary Bagot, the principal investigator at McGill University, made significant advances in neuroscience. Her lab has developed a translationally relevant mouse model to probe how stress changes the way the brain processes reward. Research using this model could have significant implications for the treatment of depression, addiction and other psychiatric disorders. We congratulate Dr. Bagot and her team on their work. We are proud to have supported Dr. Bagot's research and are excited about the possibilities that this advance could unlock.



# DE-RISKED DRUG DEVELOPMENT

PHARMACEUTICAL & MEDICAL CHANNELS

# DRUG DEVELOPMENT MEDICAL & PHARMACEUTICAL

UNIQUE FINISHED DRUG PRODUCTS UTILIZE CUBED'S MANUFACTURING CAPABILITIES TO CREATE NATURAL MEDICINE WITH MULTI-API DOSING

<b>CB-001</b>	<b>CB-002</b>	<b>CB-003</b>	<b>CB-005</b>	<b>CB-006</b>
<b>PSILOCYBIN</b>	<b>OCELOT</b>	<b>AYATHEO</b>	<b>TIGRINA</b>	<b>IBOMEO</b>
Natural Psilocybin Isolate	Non-hallucinogenic Novel Hybrid Psychedelic	The Ayahuasca Pill Indication: P.T.S.D.	Psilocybin Botanical Drug	The Ancient Mix Indication: P.T.S.D. & T.B.I.
<b>99.66% PURITY</b>	<b>INDICATION: T.R.D., G.A.D., S.U.D.</b>	<b>DIMETHYLTRYPTAMINE HARMINE</b>	<b>FULL TRYPTAMINE</b>	<b>IBOGAINE + 5- MEO-DMT</b>
Intellectual Property To Out-license For Standardization	In Discovery Phase Discovered Potential Molecules	Stacked Dual API Tablet	Strain-Specific Mushroom Pill	Two Pill Protocol

# CB-001 NATURAL PSILOCYBIN ISOLATE

## NATURALLY-DERIVED ISOLATES & FULL TRYPTAMINE FORMULAS FOR MULTI-STATE & COUNTRY LEGALIZATION

- A natural psilocybin isolate at 99.66% purity purified from our proprietary in-house mushroom cultivation.
- Designed for precision dosing, enhanced bioavailability, and multi-state/country regulatory compliance.


→ API: PSILOCYBIN

→ DOSE: 1, 2, 25 MG

→ INDICATION: TREATMENT RESISTANT DEPRESSION, SUBSTANCE ABUSE DISORDER

→ CHANNEL: SPECIAL ACCESS PROGRAMS (CAN, AUS), MULTI-STATE USA (NJ, FL, OR, CO)

→ FINISHED DRUG PRODUCT: TABLET (1MG X 10, 25 MG X 1)



# CB-002 OCELOT

## HYBRID INOVEL CHEMICAL ENTITIES

- A novel chemical entity (NCE) and non-hallucinogenic hybrid psychedelic family of 50 unpatented molecules
- Engineered to harness therapeutic benefits without altered perception, ideal for wider clinical adoption.

→ API: NOVEL HYBRID PSYCHEDELIC

→ DOSE : TBD

→ INDICATION: DEPRESSION, P.T.S.D., G.A.D., S.U.D.

→ CHANNEL: FDA & HEALTH CANADA DRUG DIN#

→ FINISHED DRUG PRODUCT: TABLET



# VOYAGE THERAPEUTIC CENTERS

## MULTI-STATE OPERATIONS MEDICAL MODEL

Voyage Therapeutics will be a U.S.-based clinical subsidiary designed to scale psychedelic-assisted therapy and on-site production across legalized jurisdictions — mirroring the growth strategy pioneered by multi-state operators (MSOs) in the cannabis industry while federal legalization begins. This model enables vertically integrated delivery — from cultivation to patient care — while leveraging Cubed’s proprietary strain-specific natural psilocybin and hybrid psychedelics.

### Each center will include:

- A licensed physician
- Two registered nurses
- Ten certified psychedelic therapists
- On-site production of Cubed’s proprietary natural entheogens
- Capacity to treat 30 patients per day, per facility
- Revenue Potential:  $\$1,000/\text{client} \times 30/\text{day} \times 250 \text{ days}/\text{year} = \$7,500,000$  per clinic

### Key Potential Revenue Highlights:

Revenue-ready clinics with therapeutic throughput of 7,500 sessions per center annually

- First-mover advantage in states rolling out legal psychedelic care infrastructure
- Commercializes Cubed’s proprietary IP in natural psilocybin and other entheogens
- Alignment with federal reform trends and growing bipartisan mental health support



# VALUATION OVERVIEW\*

---

**Current Valuation: CAD \$27.8 Million** (based on last common stock issuance price of CAD \$0.45)

Based on common stock price times outstanding shares, internal financial models, comparable transactions, federal Dealers License and strategic IP portfolio.

---

## Key Valuation Drivers:

- Proprietary Manufacturing IP: Trade-secret natural psilocybin isolation process
  - Pipeline Strength: CB-001 (Natural Psilocybin), CB-002 (Non-Hallucinogenic Hybrid), and CB-005 (Full Spectrum Capsule)
  - Clinical & Regulatory Progress: Health Canada Dealer's License, IND-enabling studies underway
  - Operational Infrastructure: 18,700 sq ft GMP-grade facility in Montréal
  - Multi-Revenue Model: B2B supply, licensing, clinical care (Voyage Therapeutics)
  - Benchmarking Public & Private Comps:
    - Filament Health, Optimi, MindMed, Beckley, Atai Life Sciences, Cybin
  - Average enterprise value for early-stage psychedelic biotechs:
    - Manufacturers: \$3 to \$30M
    - Drug Developers: \$100 to \$250M
- 

## Strong Institutional Support Secured

- USD\$500,000 Convertible Debenture with strategic investors
  - Executed \$10M PIPE (Private Investment in Public Equity) non-binding term sheet
  - Executed \$15M Equity Line of Credit (ELOC) non-binding term sheet
- 

\*Valuation is subject to change based on future financing, regulatory events, and market dynamics. All forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

\* Forward-looking statements are subject to risks and uncertainties. All capital raises and listing efforts are contingent on regulatory approvals, market conditions, and ongoing compliance with SEC and exchange rules.

# CONTACT



**ADAM COAPE-ARNOLD**  
CEO & FOUNDER

 [adam@cubedbiotech.com](mailto:adam@cubedbiotech.com)

 514.592.0296

 [www.cubedbiotech.com](http://www.cubedbiotech.com)

